




STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, December 17, 2009
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
Brandon Jennings, PharmD.
Raymond Ward, M.D.
Jerome Wohleb, PharmD.

Michael Flynn, M.D.
Duane Parke, R.Ph.
Karen Gunning, PharmD.

Board Members Excused:

Kort DeLost, R.Ph.

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Zeleny, CPhT., MPH

University of Utah Drug Information Center Staff Present:

Chris Beckwith, PharmD.

John Vu, PharmD.

Other Individuals Present:

John Beaty, Boehringer Ingelheim
Sabrina Aery, BMS
Monique Hall, Pharmacy Student
Nikki Milne, Pharmacy Student
Vilayvone Thipsouvan, Pharmacy Student

Brooks Hubbard, Boehringer Ingelheim
Joann Ginal, BMS
Kyle Fox, Pharmacy Student
Michael Schoenfeld, Eli Lilly

Meeting conducted by: Raymond Ward, M.D., Co-Chairperson.

-
1. Minutes for November 2009 were reviewed, corrected, and approved. Duane moved to approve the minutes. Dr. Jennings seconded the motion. The motion was approved with votes by Dr. Wohleb, Dr. Jennings, Duane Parke, and Dr. Ward. Karen Gunning abstained from voting.
 2. Election of New Co-Chair: Last month, it was suggested that Karen would serve well as a Co-Chair. Further discussion was postponed at the time due to Karen's absence. Karen accepted the nomination. Dr. Jennings moved that Karen serve as Co-Chair. Dr. Wohleb seconded the motion. The motion was approved with votes by Dr. Wohleb, Dr. Jennings, Duane Parke, and Dr. Ward. Karen Gunning abstained from voting.
 3. Kapidex: Dr. Christina Beckwith presented the University of Utah Drug Information Service's findings on Kapidex.

Dr. Ward asked if the Committee needs to take action based on this report. Duane stated that the Committee needs to determine if there are any major differences between Kapidex and the other agents.

Dr. Wohleb asked if there was any information available on bioavailability. Dr. Beckwith stated that there is no data available, but that it is safe to assume that it is comparable to Lansoprazole due to its similarity.

Karen Gunning moved that there are no differences in safety and efficacy between Kapidex and other existing agents in the class. Duane Parke seconded the motion. The motion was approved with votes by Dr. Wohleb, Dr. Jennings, Duane Parke, Dr. Gunning, Dr. Brownstein, and Dr. Ward.

4. Antiplatelet Agents: Dr. John Vu of the University of Utah Drug Information Service presented the Oregon Health Sciences University Class Review from 2007 and the University of Utah's separate review of prasugrel.

Dr. Michael Schoenfeld from Eli Lilly addressed the Committee on the label information, safety, and benefits of Effient.

Dr. Jon Beaty of Boehringer Ingelheim addressed the Committee on the label information, safety, and benefits of Aggrenox.

Dr. Joann Ginal of Bristol-Meyers Squibb addressed the Committee on the label information, pharmacogenetics, safety, and benefits of Plavix.

Karen asked for clarification on the safety issues on ticlopidine, since her impression has always been to not use ticlopidine. Dr. Vu stated that clopidogrel should not be the preferred agent due to neutropenia, and should be reserved for patients with hypersensitivity to clopidogrel.

Karen moved to exclude ticlopidine from the PDL due to safety issues compared to the other agents. Dr. Flynn seconded the motion. The motion was approved with votes by Dr. Wohleb, Dr. Jennings, Duane Parke, Dr. Gunning, Dr. Brownstein, and Dr. Ward.

Dr. Wohleb stated that at his work, the class was recently reviewed, and differences in safety and efficacy were found between prasugrel and other agents in the class. Karen indicated that this class had some issues with differing indications as well that would make it difficult to select a preferred agent or agents. Karen felt that all of them should be included, and that appropriate uses for specific indications are more of a DUR Board issue. The P&T Committee agreed with her opinions.

The P&T Committee felt that it may be best to defer judgment on prasugrel should be withheld until further studies are available on safety. In the meanwhile, Duane could contract for secondary rebates with any of the three agents that have them available.

Duane moved to include all three agents on the PDL, and re-address the issue

when more data is available on the safety of prasugrel. Dr. Brownstein seconded the motion. The motion was approved with votes by Dr. Wohleb, Dr. Jennings, Duane Parke, Dr. Gunning, Dr. Brownstein, and Dr. Ward.

Next Meeting Set for Thursday, February 18, 2010
Meeting Adjourned.

Minutes prepared by Jennifer Zeleny